Scholar Rock Holding Corporation (SRRK) Covered Calls

You can sell covered calls on Scholar Rock Holding Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for SRRK (prices last updated Tue 4:16 PM ET):

Scholar Rock Holding Corporation (SRRK) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
27.86 +1.48 24.80 27.85 765K - 2.5
Covered Calls For Scholar Rock Holding Corporation (SRRK)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Dec 20 30 1.65 26.20 6.3% 71.9%
Jan 17 30 2.20 25.65 8.6% 52.3%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, a novel inhibitor of the activation of myostatin, which is in Phase II clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.